Key result
A new class of drugs targeting the specific pathophysiology of obstructive hypertrophic cardiomyopathy provides novel therapeutic options following decades of stagnant medical treatment.
Why the study?
Typical medical treatment for hypertrophic cardiomyopathy has been stagnant for decades despite advances in surgical management.
This review summarizes new pharmacological therapies targeting the specific pathophysiology of obstructive hypertrophic cardiomyopathy.
May expand options in obstructive HCM; leaves open need for RCT confirmation before practice change.
Hypertrophic cardiomyopathy (HCM) is a phenotypically heterogeneous disease with a genetic basis and variable penetrance. The hallmarks of HCM include dynamic left ventricular outflow tract obstruction, typically caused by asymmetric septal hypertrophy. However, abnormal papillary muscle placement, abnormal mitral valve and subvalvular apparatus and apical hypertrophic forms have also been described. Typical medical treatment has been stagnant for decades, although there have been significant advances in surgical treatment of patients with obstructive HCM. Herein, we describe a new class of drugs targeting the specific pathophysiology of HCM.
No takes yet. Share an insight, caveat, or question.
Mehra et al. (2023) conducted a review in Obstructive Hypertrophic Cardiomyopathy. New class of drugs targeting HCM pathophysiology was evaluated. A new class of drugs targeting the specific pathophysiology of obstructive hypertrophic cardiomyopathy provides novel therapeutic options following decades of stagnant medical treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: